Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Clinical trial NCT04239625 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04239625
Sponsor: Alkeus Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stargardt Disease Stargardt Macular Degeneration Stargardt Macular Dystrophy Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Start date: 2019-12-20
Primary completion: 2026-12-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.